Researcher Spotlight: Brian Hess, MD Medical University of South Carolina A common treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is salvage chemotherapy followed by an autologous stem cell transplant (a transplant of a patient’s own healthy cells).…
Researcher Spotlight: Raghuveer Ranganathan, MD University of North Carolina, Chapel Hill Though CAR T-cell therapy has been successful for many patients with Non-Hodgkin lymphomas, the nature of the two versions currently approved by the FDA can have some severe side…
Researcher Spotlight: Neha Mehta-Shah, MD Washington University in Saint Louis Peripheral T-cell lymphomas (PTCL) are a rare group of lymphomas that are commonly treated with combination chemotherapy, followed by autologous stem cell transplant for patients with a good response. However,…
Researcher Spotlight: Anita J. Kumar, MD, MSCE Tufts Medical Center For most Hodgkin lymphoma (HL) patients, chemotherapy is the standard treatment. However, patients often have their initial treatment plan modified (through dose adjustment or delays in treatment) due to concerns…
Researcher Spotlight: Jean L. Koff, MD, MS Winship Cancer Institute Post-transplant lymphoproliferative disorder (PTLD) is a type of lymphoma that may occur in patients who have undergone stem cell or organ transplants. While some PTLD patients are cured simply with…
Researcher Spotlight: Rui Wu, MD, PhD University of Pennsylvania Perelman School of Medicine Anaplastic large cell lymphoma (ALCL) is a rare type of NonHodgkin lymphoma and one of the subtypes of T-cell lymphoma. While current therapies help many patients, as…
Researcher Spotlight: Gabriele Varano, PhD Icahn School of Medicine at Mount Sinai Researchers have found the protein FOX01 is mutated in several types of aggressive B-cell Non-Hodgkin lymphoma, but the role these mutations play in lymphoma development is not fully…
Researcher Spotlight: Nathan Ungerleider, PhD Tulane University School of Medicine The Epstein-Barr virus (EBV) has been shown to be linked to the development of Burkitt lymphoma, an aggressive B-cell lymphoma. EBV-infected cells are particularly efficient, capable of altering normal cells…
Researcher Spotlight: Irene Scarfo, PhD Massachusetts General Hospital The majority of chimeric antigen receptor (CAR) T-cell therapies currently being tested in lymphoma, including both therapies that have received U.S. Food and Drug Administration (FDA) approval, target CD19 antigen, and rely…
Researcher Spotlight: Teresa Sadras, PhD Beckman Research Institute City of Hope Though chronic lymphocytic leukemia (CLL) patients with indolent (slow-growing) forms of the disease have a high rates of long-term survival, patients with more aggressive forms of CLL have significantly…